Cagrilintide
Synthetic peptide studied in clinical and preclinical models for clinically significant weight reduction and novel appetite regulation pathway
Last updated: March 1, 2026
- Compound
- Cagrilintide
- Class
- Body Composition peptide
- Summary
- Synthetic peptide studied in clinical and preclinical models for clinically significant weight reduction, novel appetite regulation pathway, glycemic control.
- Mechanism
- Sustained Action via Acylation
- Research Status
- Phase III
- Routes Studied
- Subcutaneous injection
- Evidence Level
- Late-stage clinical · Clinically tested
What Should You Know About Cagrilintide?
- What is Cagrilintide?
- Cagrilintide is a synthetic peptide studied in clinical and preclinical models for clinically significant weight reduction and novel appetite regulation pathway.
- Is Cagrilintide clinically proven?
- No. Human evidence remains limited and does not establish Cagrilintide as clinically proven. See the full evidence review for a study-by-study breakdown.
- What has Cagrilintide been studied for?
- Cagrilintide has been studied in clinical and preclinical settings of clinically significant weight reduction, novel appetite regulation pathway, glycemic control. Late-stage clinical trials have been conducted, though final regulatory outcomes may vary by jurisdiction.
- Is Cagrilintide approved?
- Cagrilintide is in late-stage clinical development but has not yet received full regulatory approval in all jurisdictions. Consult a local specialist for current status.
What Is Cagrilintide?
Cagrilintide is a long-acting acylated analogue of amylin, a 37-amino-acid peptide hormone naturally co-secreted with insulin from pancreatic beta cells in response to food intake. While amylin has been recognized since the late 1980s as a key regulator of post-meal glucose metabolism and satiety signaling, its therapeutic potential was limited by the native hormone's extremely short half-life of approximately 13 minutes. Cagrilintide overcomes this limitation through fatty acid acylation, extending...
Evidence Summary
Cagrilintide has reached late-stage clinical trials (Phase III). Substantial human data exists, though final regulatory outcomes may still be pending.
Evidence Breakdown
| Domain | Evidence Level |
|---|---|
| Clinically Significant Weight Reduction | Limited |
| Novel Appetite Regulation Pathway | Limited |
| Glycemic Control | Limited |
| Convenient Once-Weekly Dosing | Limited |
| Human clinical evidence | Substantial |
| Safety data | Insufficient |
| Deep Research Score | 3.0 / 5 See full review |
Editorial Position
Cagrilintide is best understood as a compound with emerging clinical evidence that has not yet reached definitive conclusions. Many online claims exceed the strength of available human evidence, and safety data remains incomplete. Any consideration of this compound should involve careful evaluation of individual context and medical guidance.
Regulatory Status Snapshot
- Late-stage clinical trials conducted; not yet approved in all jurisdictions
- Safety data from clinical trials available but regulatory review ongoing
Need help interpreting this evidence for your situation?
Talk to a SpecialistWant the Full Scientific Evidence Review?
View the full scientific evidence review of Cagrilintide with study-by-study analysis, evidence strength ratings, and independent editorial verdicts.
View full scientific evidence review of CagrilintideWhat Has Cagrilintide Been Studied For?
Research areas where Cagrilintide has been investigated in published studies
-
Clinically Significant Weight Reduction Cagrilintide has been studied in clinical and preclinical studies of clinically significant weight reduction.
-
Novel Appetite Regulation Pathway Cagrilintide has been studied in clinical and preclinical studies of novel appetite regulation pathway.
-
Glycemic Control Cagrilintide has been studied in clinical and preclinical studies of glycemic control.
-
Convenient Once-Weekly Dosing Cagrilintide has been studied in clinical and preclinical studies of convenient once-weekly dosing.
How Does Cagrilintide Work?
These mechanisms have been studied in clinical and preclinical settings. Clinical trials are ongoing or completed.
- 01 Amylin Receptor Complex Binding
- 02 Central Appetite Suppression
- 03 Gastric Emptying Modulation
- 04 Glucagon Suppression
Not sure if Cagrilintide is right for you?
A specialist can review the evidence, evaluate your medical context, and help you make an informed decision about Cagrilintide.
Community Reports (Anecdotal)
Experiences shared here are self-reported and do not represent clinical evidence.
Rate Cagrilintide
How Is Cagrilintide Administered?
Cagrilintide is available via Subcutaneous injection. Appropriate use and protocol should be determined by a qualified specialist.
What Are the Specifications of Cagrilintide?
What Conditions Has Cagrilintide Been Linked To?
Have Questions About Cagrilintide?
Phase II trials published in The Lancet demonstrated dose-dependent weight loss up to 10.8% over 26 weeks. The Phase III REDEFINE program studying cagrilintide combined with semaglutide has shown up to 22.7% body weight reduction.
Cagrilintide is a research compound that should only be used under qualified medical supervision. Baseline metabolic assessment including fasting glucose, HbA1c, lipid panel, liver function, and body composition analysis is essential.
Published studies on Cagrilintide can be found on PubMed and other peer-reviewed databases. Our references section below lists key citations.
What Does the Published Research Say?
-
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
-
CagriSema once weekly versus semaglutide once weekly in adults with overweight or obesity (REDEFINE 1): a randomised, open-label, phase 3 trial
-
Amylin and calcitonin: pharmacology and prospects for clinical application
Ready to discuss Cagrilintide with a specialist?
Get evidence-based guidance tailored to your health goals and medical context.
Book a Consultation Free initial consultation. No obligation.Reviewed by the Peptide Science Thailand Editorial Team.
Last reviewed: March 1, 2026